| 31776465 | Bartels S, Faisal M, Büsche G, et al. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia. 2020.34(5):1364-1372. doi:10.1038/s41375-019-0668-5 |
| 26994960 | Monte-Mor Bda C, Ayres-Silva Jde P, Correia WD, et al. Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. Blood Cells Mol Dis. 2016.60:74-77. doi:10.1016/j.bcmd.2016.03.003 |
| 26377485 | Wang J, Hao J, He N, Ji C, Ma D. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia. Miyeloproliferatif Neoplazisi ve Akut Lösemisi Olan Hastalarda Kalretikülin Mutasyon Profili. Turk J Haematol. 2016.33(3):180-186. doi:10.4274/tjh.2015.0220 |
| 24402162 | Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014.28(7):1472-1477. doi:10.1038/leu.2014.3 |
| 25190754 | Salama ME, Swierczek SI, Tashi T, Warby CA, Reading NS, Prchal JT. Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood. 2014.124(10):1691-1692. doi:10.1182/blood-2014-04-568410 |
| 32971364 | Javorniczky NR, Wehrle J, Ihorst G, et al. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leuk Res. 2020.98:106454. doi:10.1016/j.leukres.2020.106454 |
| 32395211 | Liu YC, Lee CP, Yeh TJ, et al. Calreticulin Mutation Survey by High Resolution Melting Method Associated with Unique Presentations in Essential Thrombocythemic Patients. Mediterr J Hematol Infect Dis. 2020.12(1):e2020022. Published 2020 May 1. doi:10.4084/MJHID.2020.022 |
| 25682604 | Plompen EP, Valk PJ, Chu I, et al. Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. Haematologica. 2015.100(6):e226-e228. doi:10.3324/haematol.2014.120857 |
| 27521277 | Panovska-Stavridis I, Eftimov A, Ivanovski M, et al. Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk. 2016.16(8):477-481. doi:10.1016/j.clml.2016.04.019 |
| 27855276 | Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia. J Mol Diagn. 2017.19(1):92-98. doi:10.1016/j.jmoldx.2016.08.006 |
| 25637689 | Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, et al. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015.8(1):16-21. doi:10.1016/j.hemonc.2014.12.002 |
| 24837467 | Lippert E, Mansier O, Migeon M, et al. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica. 2014.99(7):e98-e101. doi:10.3324/haematol.2014.107656 |
| 25103987 | Trifa AP, Popp RA, Cucuianu A, et al. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2015.168(1):151-153. doi:10.1111/bjh.13076 |
| 27917774 | De Kock A, Booysen C. Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm. S Afr Med J. 2016.106(12):1260-1262. Published 2016 Dec 1. doi:10.7196/SAMJ.2016.v106.i12.10769 |
| 27535857 | Xu ZF, Li B, Liu JQ, et al. Zhonghua Xue Ye Xue Za Zhi. 2016.37(7):576-580. doi:10.3760/cma.j.issn.0253-2727.2016.07.007 |
| 25323779 | Wojtaszewska M, Iwoła M, Lewandowski K. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta Haematol. 2015.133(2):193-198. doi:10.1159/000366263 |